trending Market Intelligence /marketintelligence/en/news-insights/trending/yZU-VmBz4p6TGCQHloaRxg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Exelixis gets FDA priority review to expand use of kidney cancer drug

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Exelixis gets FDA priority review to expand use of kidney cancer drug

The U.S. Food and Drug Administration granted priority review to Exelixis Inc.'s supplemental new drug application for Cabometyx to treat patients with previously untreated advanced renal cell carcinoma.

The application is based on data from a phase 2 trial. The FDA will take a decision on the drug by Feb. 15, 2018.

On April 25, 2016, Cabometyx was approved by the agency to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.